Alpha 2.0
Login Register
» Authors » O Boerman

O Boerman

Explore the profile of O Boerman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 49
Followers 0
Related Specialties
Oncology
General Surgery
Biochemistry
Top 10 Co-Authors
L Poels
M L van Slooten
P Kenemans
K Makkink
G Storm
D J Crommelin
C Thomas
L Massuger
E Kedar
L F de Geus-Oei
Published In
Anticancer Res
Biochim Biophys Acta
Clin Exp Immunol
Eur J Surg Oncol
Pharm Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach
Heijmen L, Punt C, ter Voert E, de Geus-Oei L, Heerschap A, Bussink J, et al.
Invest New Drugs . 2013 Jan; 31(4):881-90. PMID: 23325291
Clinical studies have shown that bevacizumab beyond progression to first line therapy is beneficial for overall survival in advanced stage colorectal cancer. We studied the utility of several functional imaging...
2.
Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model
de Jong G, Hendriks T, Franssen G, Oyen W, Boerman O, Bleichrodt R
Eur J Surg Oncol . 2011 Jan; 37(3):258-64. PMID: 21208773
Purpose: Radiofrequency ablation (RFA) has shown to improve survival in patients not eligible for surgical resection of colorectal liver metastases. However, recurrences after RFA are a major problem. Adjuvant radioimmunotherapy...
3.
Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects
van Slooten M, Boerman O, Romoren K, Kedar E, Crommelin D, Storm G
Biochim Biophys Acta . 2001 Mar; 1530(2-3):134-45. PMID: 11239816
Interferon-gamma (IFNgamma) has proven to be a promising adjuvant in vaccines against cancer and infectious diseases. However, due to its rapid biodegradation and clearance, its efficacy is severely reduced. Liposomal...
4.
Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines
van Slooten M, Storm G, Zoephel A, Kupcu Z, Boerman O, Crommelin D, et al.
Pharm Res . 2000 Mar; 17(1):42-8. PMID: 10714607
Purpose: Liposomal systems may be useful as a cytokine supplement in tumor cell vaccines by providing a cytokine reservoir at the antigen presentation site. Here, we examined the effect of...
5.
Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences
Slobbe R, Poels L, Ten Dam G, Boerman O, Nieland L, Leunissen J, et al.
Clin Exp Immunol . 1994 Oct; 98(1):95-103. PMID: 7523009
Two MoAbs, independently raised against ovarian carcinoma cells and referred to as OV-TL3 and OV-TL16, display an identical reaction pattern with a membrane-associated protein in both normal and malignant ovarian...
6.
Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies
Boerman O, Massuger L, Makkink K, Thomas C, Kenemans P, Poels L
Anticancer Res . 1990 Sep; 10(5A):1289-95. PMID: 2241105
The interactions of four monoclonal antibodies (OV-TL 3, OV-TL 16, OV-TL 30 and OC 125) with ovarian carcinoma cells (NIH: OVCAR-3) were compared in vitro as well as in a...
7.
Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids
Boerman O, Makkink K, Massuger L, Thomas C, Kenemans P, Hanselaar T, et al.
Anticancer Res . 1989 May; 9(3):551-8. PMID: 2764501
Intrasplenic immunization with ovarian tumour derived cyst fluids was used to generate monoclonal antibodies (Mabs) against human ovarian carcinomas. Seven Mabs were characterized immunocytochemically using indirect immunofluorescence assays (IFA) on...